Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma
Clinical Lymphoma Myeloma and Leukemia（2022）
关键词
refractory multiple myeloma,multiple myeloma,daratumumab trials,teclistamab versus physicians,long-term,triple-class
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要